The nuclear receptor REV-ERB is a promising novel, potentially disease-modifying therapeutic target for patients with dementia and neurodegenerative diseases such as FTD. Preliminary data suggest that REV-ERB agonists correct aberrant gene expression of neuroinflammatory and mitochondrial activity pathways and improve cognitive decline that is associated with these debilitating, currently irreversible diseases. With continued clinical failures observed, it is critical that we focus on therapeutics with novel mechanisms of action. Pelagos Pharmaceuticals, in collaboration with ADDF, is well-suited to bring a novel therapeutic to the clinic. The Pelagos team brings a strong disease- and target-relevant drug screening pipeline, which, as a large part because of contributions from ADDF, will ultimately yield the first clinical-stage small molecule REV-ERB agonist.